are a new class of bladder cancer detection and management tests that detect urothelial cancers including those in the upper urinary tract and renal pelvis, which are notoriously difficult to ...

Historically, open nephron-sparing surgery for upper-tract TCC was used in patients with a large renal pelvis ... transitional cell carcinoma (TCC) accounts for only 5% of urothelial malignancies ...

The most common primary site was the bladder (81.9%), followed by renal pelvis or ureter (12.0%). More than half of the patients presented with metastatic disease at diagnosis. The most commonly ...

China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.

Baizean is used for the treatment of patients with classical Hodgkin’s lymphoma (cHL) who have received at least two prior therapies and treatment for patients with locally advanced or metastatic ...

PTGER2 expression was shown to be undetected in muscle cells located in the renal pelvis. - PTGER3 was rarely detected in urothelial cells (10%) of the renal pelvis and the distal and proximal ureter.

Renal cell carcinoma (RCC) exhibits distinct clinical characteristics across its ... and BRCA2 at up to 6% in RCC patients and 11% in upper tract urothelial carcinoma patients. They noted that these ...